<DOC>
	<DOCNO>NCT02205567</DOCNO>
	<brief_summary>Bergamot-derived product show significant effect plasma lipid . We aim present study evaluate effect bergamot several cardio-metabolic risk marker .</brief_summary>
	<brief_title>Bergamot Cardio-Metabolic Risk Factors</brief_title>
	<detailed_description>The research hypothesis ass whether bergamot reduces plasma lipid ( total cholesterol , triglyceride , low-density lipoprotein ( LDL ) -cholesterol high-density lipoprotein ( HDL ) -cholesterol ) , atherogenic lipoprotein , carotid intima-media thickness ( IMT ) liver steatosis patient dyslipidemia . The primary objective ass whether bergamot reduces plasma lipid atherogenic lipoprotein patient dyslipidemia . Primary endpoint : Reduction plasma lipids atherogenic lipoprotein . The secondary objective ass whether bergamot reduces carotid intima-media thickness ( IMT ) liver steatosis patient dyslipidemia . Secondary endpoint : Reduction IMT liver steatosis . Clinical diagnostic tool include measurement : 1. cIMT , assess B-mode real-time ultrasound use single sonographer ( Medison SonoAce Pico , probe 7.5-10.0 MHz ) standardize manner fixed angle insonation ; 2. liver steatosis , assess abdominal ultrasound . Biochemical analysis include analysis : 1 . Routine test plasma lipid ; 2 . Atherogenic lipoprotein , e.g . analysis 11 distinct lipoprotein include very-low-density lipoprotein ( VLDL ) , 3 intermediate density lipoprotein ( IDL ) subclasses 7 low density lipoprotein ( LDL ) subclasses .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>elevate LDLcholesterolemia severe hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>